Welcome to Part 1 of the 5-part case-based series.
New Currents in Treatment of Bone Metastases: A Case-Based Approach
This Tx Reporter series discusses the use of bisphosphonates to help prevent skeletal-related events in patients with bone metastases from solid tumors. This first issue provides an overview of bone metastases, and the use of bisphosphonates in cancer therapy and their important role in preventing skeletal complications.
This continuing professional education activity also includes the enclosed audio CD, in which faculty discuss:
- The devastating effects of bone metastases in their various clinical populations
- Effects of bone turnover on tumor growth
- Key clinical trials of bisphosphonates
- The potential antitumor activity of bisphosphonates
- Practical guidelines for using bisphosphonates
Dear Colleague:
Skeletal complications of malignancy—bone pain, pathologic fractures, spinal cord compression, and hypercalcemia—greatly decrease quality of life and are associated with considerable morbidity and mortality. Bisphosphonates offer an effective way to help prevent skeletal-related events in patients with bone metastases from solid tumors. In this 5-part continuing education activity, New Currents in Treatment of Bone Metastases: A Case-Based Approach, leading medical oncologists discuss important data on bisphosphonates—including the newest research—and formulate specific patient-care guidelines illustrated in sample clinical cases.
This 5-part series opens with an overview of bone metastases and bisphosphonates (Part 1), and continues with four additional case-based discussions (Parts 2–5) of the use of bisphosphonates in treating skeletal complications of breast, prostate, renal, and lung cancers. This allows an in-depth look at specific patient populations and information on applying the data on bisphosphonates to actual clinical practice.
Each issue in this 5-part series consists of a Tx Reporter newsletter, an audio CD featuring an interview of the expert faculty on related issues, and a recent reprint with information that has largely determined the current standard of care. These issues focus on the next generation of bisphosphonate therapy. However, fair balance is critical to this discussion, and the faculty and I also present data on other bisphosphonates.
Here in Part 1 you will find a thorough overview explaining why specific management of bone metastases to prevent skeletal complications is so important. The discussion of bisphosphonates will provide you with an overview of the key data and clinical guidelines that will be explored more in depth in the case studies that follow in Parts 2 through 5. I hope that you enjoy the series and find it helpful and informative.
Yours truly,
Chair
James R. Berenson, MD
Chief Executive Officer
Institute of Cancer Therapies
Los Angeles, California |
|
 |
|
Faculty
Mark R. Green, MD
Gilbreth Professor of Clinical Oncology
Medical University of South Carolina
Charleston, South Carolina
Allan Lipton, MD
Professor of Medicine/Oncology
Penn State University
Milton S. Hershey Medical Center
Hershey, Pennsylvania
Celestia S. Higano, MD
Associate Professor of Medicine and Urology
University of Washington
Seattle Cancer Center Alliance
Seattle, Washington
|
|
|
top
Target Audience
This activity is designed for oncologists and oncologic healthcare professionals who treat patients with bone metastases.
Activity Goal
The goal of this activity is to provide an overview of bone metastases and the latest developments in preventing related skeletal complications using bisphosphonate therapies.
Learning Objectives
After completing this activity, the participant should be able to:
- Review the incidence of bone metastases in patients with metastatic cancer, including multiple myeloma, breast, prostate, lung, kidney, thyroid, and other solid tumors.
- Describe the complications imposed by bone metastases in the clinical management of various solid tumors.
- Examine the mechanisms of action of bisphosphonates and their role in improving bone strength and inhibiting malignant cell function.
- Discuss the safety and efficacy of currently available agents and next generation bisphosphonates.
- Consider the use of intravenous therapy in the treatment armamentarium to delay and reduce skeletal complications of bone metastases in patients with multiple myeloma, breast, prostate, lung, kidney, thyroid, and other solid tumors.
- Describe appropriate techniques for administration of intravenous bisphosphonates.
- Improve quality of life for patients with bone metastases.
top
CME Information
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. Projects In Knowledge designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
CPE Information
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to this program, for 1 contact hour (0.1 CEU), is 052-000-03-053-H01.
CE Information
The National Center for Advanced Medical Education (a division of CMEinfo.com) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The National Center for Advanced Medical Education (a division of CMEinfo.com) designates this educational activity for 1.2 contact hours. Provider approved by the California Board of Registered Nursing, Provider Number 13776 for 1.2 contact hours.
top
Disclosure Information
The Disclosure Policy of Projects In Knowledge and The National Center for Advanced Medical Education (a division of CMEinfo.com) requires that the faculty participating in a CME/CPE/CE activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.
James Berenson, MD, has received grant/research support from, is a consultant for, and is on the speakers bureau of Ariad Pharmaceuticals, Celgene Corporation, Cell Therapeutics, Inc, Chugai Pharmaceuticals Company, Millennium Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation. Mark R. Green, MD, is a consultant for Novartis Pharmaceuticals Corporation. Celestia S. Higano, MD, has received grant/research support from Abbott Laboratories, Abgenix, Inc, Amgen Inc, Aventis Pharmaceuticals, Cell Genesys, Inc, Cell Pathways, Inc, Dendreon, Eli Lilly and Company, Medarex, Inc, Novacea, Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals Inc, Transgene, and Xcyte Therapies. Allan Lipton, MD, is on the speakers bureau of and is a stock shareholder in Novartis Pharmaceuticals Corporation. Christine Wilson, PhD, APRN, BC, NP-C, is on the speakers bureau of Bristol-Myers Squibb Company; and is a stock shareholder in Pfizer Inc. Susan Bove, MS, APRN, BC, has no significant relationships with industry.
The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge, The National Center for Advanced Medical Education (a division of CMEinfo.com), or the funder.
This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data.
This CME/CPE activity is provided by Projects In Knowledge, and the CE activity is provided by The National Center for Advanced Medical Education (a division of CMEinfo.com), solely as an educational service. Please note that although faculty will discuss specific treatment modalities, neither Projects In Knowledge, the accredited and approved CME provider, nor The National Center for Advanced Medical Education (a division of CMEinfo.com), the accredited and approved CE provider, nor their CME/CE regulatory bodies, including the ANCC, endorse any of the modalities mentioned in the course of discussion. Specific patient care decisions are the prerogative of the healthcare professional caring for the patient.
This independent CME/CPE/CE activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
top